Eye treatment – Antares Optical http://www.antaresoptical.com/ Tue, 17 May 2022 22:33:30 +0000 en-US hourly 1 https://wordpress.org/?v=5.9 https://www.antaresoptical.com/wp-content/uploads/2022/04/icon-150x105.png Eye treatment – Antares Optical http://www.antaresoptical.com/ 32 32 Innovative EverTears® Dry Eye Treatment Endorsed by Dr. Pam Theriot in Independent Strong https://www.antaresoptical.com/innovative-evertears-dry-eye-treatment-endorsed-by-dr-pam-theriot-in-independent-strong/ Tue, 17 May 2022 14:45:00 +0000 https://www.antaresoptical.com/innovative-evertears-dry-eye-treatment-endorsed-by-dr-pam-theriot-in-independent-strong/ An industry leader in the treatment of Meibomian Gland Dysfunction and Dry Eye Syndrome has received influential endorsement. ATLANTA, GEORGIA, USA, May 17, 2022 /EINPresswire.com/ — Representatives of ThermaMEDx today announced that its product, EverTears®the world’s first combination of self-heating eye pad and pre-moistened cleansing pad, has received the endorsement of an influential physician. Ben […]]]>

An industry leader in the treatment of Meibomian Gland Dysfunction and Dry Eye Syndrome has received influential endorsement.

ATLANTA, GEORGIA, USA, May 17, 2022 /EINPresswire.com/ — Representatives of ThermaMEDx today announced that its product, EverTears®the world’s first combination of self-heating eye pad and pre-moistened cleansing pad, has received the endorsement of an influential physician.

Ben Nobles, co-founder of ThermaMEDx and former senior executive at optical industry giant Alcon, shared that EverTears® is designed to provide a convenient and affordable OTC dry eye solution that delivers the precise, controlled heat and eyelid cleansing found in many in-office treatments. EverTears® takes advantage of patented technology developed by ThermaMEDx co-founder, Dr. Michel Guillon, to not only relieve dry eye symptoms, but also to help restore the eye’s natural tear film when used as directed. instructions.

Dr. Pam Theriot, in Independent Strong, listed EverTears® as an effective product to offer to patients for home use. She noted that EverTears® is “A sterile eyelid cleansing pad with a thermal component that stays at over 108 degrees for over six minutes. The pads work to unblock eyelid glands, restore oil flow and retain the natural tear layer. Moist heat melts away buildup and opens pores.”

Independent Strong is an online resource providing the information independent eyecare professionals need to thrive now and in the future. Independent Strong provides the step-by-step guidance that new and established private optometrists and opticians need to build and maintain a systematic structure and aims to serve as the foundation of their business for years to come. It also provides updated feature articles with engaging and current best practice advice on a variety of topics categorized in practice management, practice growth strategies, and ophthalmic products.

New business and practice advisory information released regularly by industry experts and partners helps private practitioners make their independent practices as successful and useful as possible.

For more information, please visit thermamedx.com/about-us

About ThermaMEDx

ThermaMEDx was founded to bring Dr. Michel Guillon’s vision of harnessing thermal energy to provide an accessible and effective treatment for dry eyes and meibomian gland dysfunction. ThermaMEDx is a family business led by our Medical Board of renowned physicians whose mission is to improve patient outcomes by striving to provide the best treatment for dry eyes caused by Meibomian Gland Dysfunction (MGD) available. for home use.

Contact details:

3343 Peachtree Road NE
ETS 145-409
Atlanta, Georgia 30326
United States

Carl Sweat
ThermaMEDx, LLC
+1 833-937-9393
write to us here


Source link

]]>
Protruding Eye Treatment Market Size 2022-Industry Opportunities and Challenges, Global and Regional Analysis by Key Industry Players https://www.antaresoptical.com/protruding-eye-treatment-market-size-2022-industry-opportunities-and-challenges-global-and-regional-analysis-by-key-industry-players/ Tue, 10 May 2022 11:36:05 +0000 https://www.antaresoptical.com/protruding-eye-treatment-market-size-2022-industry-opportunities-and-challenges-global-and-regional-analysis-by-key-industry-players/ A new market study on Global bulging eye treatment market 2022 with + data tables, pie chart and graphs is published to provide a comprehensive assessment of the market highlighting evolving trends, current and future scenario analysis and growth factors validated with expert view. The study breaks the market in terms of revenue and volume […]]]>

A new market study on Global bulging eye treatment market 2022 with + data tables, pie chart and graphs is published to provide a comprehensive assessment of the market highlighting evolving trends, current and future scenario analysis and growth factors validated with expert view. The study breaks the market in terms of revenue and volume (if applicable) and historical price estimates for Bulging Eye Treatment. Protruding Eye Treatment Market analysis report helps increase sales through new thinking, new skills, and innovative programs and tools. Through the study of Competitor Analysis, the Eye Cream industry can gain knowledge of the strategies of key players in the market, which include but are not limited to new product launches, expansions , agreements, joint ventures, partnerships and acquisitions.

Connect with market leaders and emerging players inThis market.

To learn more about market size, share, growth, trends and company profile analysis, please download our free sample report @ @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-bulging-eye-treatment-market

(Sample of this report is readily available on demand with Impact of COVID-19 on this Industry)

Content of this sample report:
? A brief introduction to this research scope and methodology.
? Revenue analysis of leading and emerging players.
? Key highlights of growth drivers and market trends.
? Key overview of the final study.
? Graphic illustration of regional analysis.

The bulging eye treatment market The report encompasses the general idea of ​​the global Protruding Eye Treatment market including definition, classifications, and applications. Also, it includes comprehensive understanding of several factors such as drivers, restraints, and major micro markets. The report is an extensive source of popular facts and figures for business strategists as it offers historical and futuristic data such as demand & supply data, cost, revenue, profit, value of supply chain, etc. Additionally, it features key market features including production, revenue, price, capacity, gross margin, market share, consumption, gross rate, production rate, demand/ supply, cost, capacity utilization rate, export/import and CAGR (annual compound). Rate of growth). Further, the report encompasses segmentation of the global bulging eye treatment market on the basis of various facets such as product/service type, application, technology, end-users and major geographical regions North America, Europe, Asia-Pacific and Latin America. Apart from this, the researcher market analyst and experts present their outlook or ideas on product sales, market share, and value, and possible opportunities for growth or operation in these regions.

Bulging Eyes Treatment Market Scenario

Bulging eye is also known as exophthalmos, a serious eye condition characterized by the protrusion of one or both eye sockets due to swelling of the tissues behind and around the eye. This causes the cornea to push forward and makes it more difficult for the eyes to get moisture and lubrication. In most cases, bulging eyes can create a large amount of pressure on the optic nerve, potentially leading to vision loss.

Key segmentation:

By treatment (drugs, surgery)

By medication (corticosteroids, antibiotics and others)

By drug type (prescription only, over-the-counter drugs)

By route of administration (oral, topical and others)

By end users (hospitals, home care, specialist clinics, others)

Major players operating in the bulging eye treatment market are:

Horizon Therapeutics plc Santen Pharmaceutical Co., Ltd

Bausch Health

Kala Pharmaceuticals

Pharmos Corp.

Akorn, Incorporated, Novartis SA

ALLERGAN

Eyevance Pharmaceuticals LLC

Noveome Biotherapeutics, Inc.

…..

The full report is available (including full table of contents, list of tables and figures, charts and graph) @https://www.databridgemarketresearch.com/toc/?dbmr=global-bulging-eye-treatment-market

The bulging eye treatment market report also involves a vigorous assessment of the growth plot and all the opportunities and risks related to the global bulging eye treatment market during the forecast period. In addition, the report includes key events and up-to-the-minute industry innovations, as well as forward-looking trends of technological advancement within the Global Eyebrightness Treatment Market that may impact its expansion graph. Containing the essential data on statistics and market dynamics, the report will be a valuable asset in terms of decision-making and guidance for companies and companies already active in the industry or wishing to enter it.

Promising Regions & Countries Mentioned In The Swelling Eyes Treatment Report:

North America ( United States)

Europe (Germany, France, United Kingdom)

Asia Pacific (China, Japan, India)

Latin America (Brazil)

The Middle East and Africa

For more information or query or customization before buying, visit @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-bulging-eye-treatment-market

Market factors

The increasing prevalence of hyperthyroidism cases and related complications is driving the growth of this market

Introducing new delivery routes that improve drug efficacy can boost the market growth

Advances in nutrition, antibiotics and new treatments are driving the market growth

Huge financial support to researchers for development of new intervention enhances market growth

Market constraints

The anatomical and physiological barrier of the eyes that makes it difficult to obtain therapeutic benefits is restraining the growth of the market

The lesser effectiveness of available treatments hammers the growth of the market

Scientific and technological challenges to develop a new treatment acting as a challenge factor for the growth of this market

Reason to buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Eye Care Market.

Highlights key business priorities to help companies realign their business strategies.

The key findings and recommendations highlight crucial progressive industry trends in the Bulging Eye Treatment, thereby allowing players to develop effective long term strategies.

Develop/modify business expansion plans using substantial growth offering in both developed and emerging markets.

Dig deep into the global market trends and outlook associated with the factors driving the market, as well as those hindering it.

Improve the decision-making process by understanding the strategies that drive business interest with respect to products, segmentation, and industry verticals.

Access the full report directly @https://www.databridgemarketresearch.com/checkout/buy/singleuser/global-bulging-eye-treatment-market

In addition, the research report examines:

Competitive companies and manufacturers in the global market

By product type, applications and growth factors

Industry status and outlook for major applications/end-users/usage area

Containment and care products and other dental consumables Table of contents

Report Overview: It includes the objectives and scope of the study and provides highlights of key market segments and players covered. It also includes the years considered for the research study.

Executive Summary: It covers industry trends with a focus on market use cases and key market trends, market size by region and global market size. It also covers market share and growth rate by region.

Key Players: Here, the report focuses on mergers and acquisitions, expansions, analysis of key players, date of establishment of companies and areas served, manufacturing base and revenue of key players.

Breakdown by Product and Application: This section provides market size details by product and application.

Regional Analysis: All of the regions and countries analyzed in the report are studied on the basis of market size by product and application, key players and market forecast.

International Player Profiles: Here, players are rated based on their gross margin, price, sales, revenue, activity, products and other company information .

Market Dynamics: It includes supply chain analysis, regional marketing analysis, challenges, opportunities, and drivers analyzed in the report.

Main results of the research study

Appendix: It includes details of the research approach and methodology, research methodology, data sources, study authors and a disclaimer.

Browse Full Report Details @https://www.databridgemarketresearch.com/reports/global-bulging-eye-treatment-market

Thank you for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Data Bridge Market Research allows you to customize the reports according to your needs. This report can be customized to meet your needs. Contact our sales team (Corporatesales@databridgemarketresearch.com), who will guarantee you get a report that suits your needs.


Source link

]]>
Dry eye treatment improves signs and symptoms at 1 week https://www.antaresoptical.com/dry-eye-treatment-improves-signs-and-symptoms-at-1-week/ Tue, 03 May 2022 20:08:10 +0000 https://www.antaresoptical.com/dry-eye-treatment-improves-signs-and-symptoms-at-1-week/ Source/Disclosures Published by: Source: Wirta D, et al. Dry eye signs, symptoms and quality of life improvements associated with AR-15512 administration. Presented at the Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver. Disclosures: Wirta reports receiving a grant from Aerie Pharmaceuticals as the principal investigator for this study. […]]]>


Source/Disclosures

Source:

Wirta D, et al. Dry eye signs, symptoms and quality of life improvements associated with AR-15512 administration. Presented at the Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver.


Disclosures: Wirta reports receiving a grant from Aerie Pharmaceuticals as the principal investigator for this study.


We have not been able to process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

DENVER – A large Phase 2b study has shown that using Aerie Pharmaceuticals’ compound AR-15512 resulted in improved tear production and dry eye symptoms at 7 days and 14 days, according to David Wirtone, MD, from the Eye Research Foundation.

The cold thermoreceptor agonist TRPM8 affects receptors in the conjunctiva, cornea and eyelid to stimulate a feeling of coldness in the eye, resulting in reflex tearing, Wirta said.


Source link

]]>
Bloated eye treatment market to grow at a torrid pace, key players -Bausch Health. – ManufactureLink https://www.antaresoptical.com/bloated-eye-treatment-market-to-grow-at-a-torrid-pace-key-players-bausch-health-manufacturelink/ Mon, 02 May 2022 10:22:03 +0000 https://www.antaresoptical.com/bloated-eye-treatment-market-to-grow-at-a-torrid-pace-key-players-bausch-health-manufacturelink/ New York, United States: A new report from Critical market insights examine the Booming eye treatment market from a global perspective and analyzes industry trends and prospects. Primary and secondary research analysis could be included in this report, which will provide market size, dynamics and forecast for different segments and sub-segments considering both macro and […]]]>

New York, United States: A new report from Critical market insights examine the Booming eye treatment market from a global perspective and analyzes industry trends and prospects. Primary and secondary research analysis could be included in this report, which will provide market size, dynamics and forecast for different segments and sub-segments considering both macro and micro factors. Extensive research on historical trends, projected trends, demographics, technological developments, and regulatory requirements have all been reviewed to determine market expansion rates for each segment and sub-segment.

Quickly take advantage of limited sample copies of the Booming eye treatment market report: visit @ https://www.decisivemarketsinsights.com/bulging-eye-treatment-market/36872504/request-sample

Protruding Eye Treatment Market Segmentation-
By type:
Medicine, Surgery
Per application:
Oral, topical and others
By key players: Bausch Health, Kala Pharmaceuticals, Pharmos Corp, Akorn, Incorporated, Novartis AG, ALLERGAN, Eyevance Pharmaceuticals LLC, Noveome Biotherapeutics, Inc, OCUNEXUS THERAPEUTICS, INC, Alcon, Merck & Co

The report contains substantial details about the functioning of the parent market. The report provides accurate projections of market size and volumes in the present and future. During the forecast period, our analysts provide our clients with comprehensive data to help them create growth plans and policies that enhance growth. The findings of our in-depth study of the world Booming eye treatment market reveal the economic cycle and paradigm shifts related to Covid-19. A number of key findings from the report are offered, shedding light on trends that may have a significant impact on the market growth ahead.

To inquire about the discount, please fill out the form by clicking the link below:- https://www.decisivemarketsinsights.com/bulging-eye-treatment-market/36872504/request-discount

This global Booming eye treatment market How will the report benefit you?
• Statistical data is provided in terms of value (US dollars) and volume (units) up to 2027.
• A detailed analysis of global trends affecting the XX market, although the major threats, opportunities, and disruptive technologies may influence global demand and supply.
• In the report on Booming eye treatment market primary and secondary data sources are combined to analyze the data.
• Using this report, you can determine the true effects of major market forces or trends on Booming eye treatment market .
• We accumulate adequate data by conducting extensive primary research with C-level executives from top companies.
• The report tracks and profiles key market players who will shape and affect the global market in the coming years.

Please click on the link below if you intend to make a direct purchase @:-https://www.decisivemarketsinsights.com/bulging-eye-treatment-market/36872504/buy-now

The report also contains several other key points, including:
• An analysis of the competitive landscape is also included in the report.
• A detailed analysis of key players’ product offerings and strategies is provided in this report.
• The report presents historical, current and projected market sizes in terms of volume and value.
• The report includes a detailed explanation of recent industry developments and trends.
• By studying the strategies used by market players to maintain and strengthen their footprint, readers gain a comprehensive understanding of their actions.
• A segment with high growth potential, as well as a region, will be analyzed.
• This report also analyzes market dynamics and details with detailed information.

In order to make a pre-order request, please click on the link below:-https://www.decisivemarketsinsights.com/bulging-eye-treatment-market/36872504/pre-order-enquiry

Please contact us and our expert will get back to you within 30 minutes:

Critical market insights
Sunil Kumar
Head of sales
E-mail -[email protected]
Website-https://www.decisivemarketsinsights.com/
United States +18317045538
UK +441256636046
Address:- 26 Broadway, Suite 934, New York, 10004

Social connections:
Twitter-https://twitter.com/decisivemarket

Linkedin-https://www.linkedin.com/company/decisive-markets-insights



Source link

]]>
Emirates News Agency – 33 million beneficiaries thanks to Noor Dubai eye treatment and prevention programs worldwide https://www.antaresoptical.com/emirates-news-agency-33-million-beneficiaries-thanks-to-noor-dubai-eye-treatment-and-prevention-programs-worldwide/ Fri, 29 Apr 2022 11:40:22 +0000 https://www.antaresoptical.com/emirates-news-agency-33-million-beneficiaries-thanks-to-noor-dubai-eye-treatment-and-prevention-programs-worldwide/ DUBAI, 29th April, 2022 (WAM) — The Noor Dubai Foundation, one of the Mohammed bin Rashid Al Maktoum Global Initiatives, has managed to benefit 33 million people worldwide, through its treatment, prevention and awareness specializing in the prevention of blindness. This was reported at the annual meeting of the Mohammed bin Rashid Al Maktoum Global […]]]>

DUBAI, 29th April, 2022 (WAM) — The Noor Dubai Foundation, one of the Mohammed bin Rashid Al Maktoum Global Initiatives, has managed to benefit 33 million people worldwide, through its treatment, prevention and awareness specializing in the prevention of blindness.

This was reported at the annual meeting of the Mohammed bin Rashid Al Maktoum Global Initiatives Foundation, where an inspiring patient story was shared, also documenting Noor Dubai’s journey since its launch in 2008.

His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President, Prime Minister and Ruler of Dubai, tweeted on his personal account yesterday expressing his pride that 145,000 volunteers have joined the initiatives in 2021, while His Highness also tweeted, ” proud of Noor Dubai which has reached 33 million beneficiaries.”

Since its launch as an initiative by His Highness Sheikh Mohammed bin Rashid Al Maktoum in 2008, Noor Dubai has helped care for those in need in 22 countries around the world, supporting humanitarian efforts and community prosperity. Following the success of the initiative in its first year, HH launched Noor Dubai as a foundation in 2010.

Despite the progress made by Noor Dubai and other institutions in this area, there is still a need to provide eye care services to those in need. According to statistics published by the World Health Organization, 295 million people worldwide suffer from visual impairment, 80% of them can be treated or prevented from developing visual impairment and 90% of people with visual impairment reside in developing countries.

Despite the challenges facing the world, especially the humanitarian sector, due to the spread of the Covid-19 pandemic globally, Noor Dubai was able to overcome all the challenges in one year and exceed its targeted beneficiaries to reach 33 million beneficiaries in a short time. of time.

The Noor Dubai Foundation programs focus on supporting the acceleration of United Nations Sustainable Development Goals 1, 3, 4, 5, 17 by developing programs and strategies for eye health in Africa and around the world. Asia that aim to empower the local community to control the disease, which will have a positive impact on the economic development of the countries where the treatment took place.

Nationally, the Foundation provides free eye screenings and consultations to the UAE community through the Mobile Eye Clinic program, which has benefited 30,050 patients since the program launched in 2014.

The clinic aims to offer eye exams to patients in their place in various parts of the country through the implementation of prevention campaigns.

The campaigns mainly focus on public transport drivers, community schools and work accommodation to ensure that eye exam services are accessible to all members of the community.

The Foundation also provides treatment to UAE residents who suffer from serious eye diseases through the UAE Treatment Program, which has successfully provided treatment to 245 patients since its launch in 2016.

Globally, the Noor Dubai Foundation runs Mobile Eye Camps in remote areas of Asia and Africa, where the lack of healthcare infrastructure and sanitation resources in these remote areas, in addition to extreme poverty, makes it difficult for patients to access the services they need. 319,280 patients benefited from the program through diagnostic and treatment services.

The Noor Dubai Foundation is also continuing its journey in the fight against neglected tropical diseases through the trachoma eradication program in northern Ethiopia. The Foundation succeeded in eliminating trachoma as a public health problem in 29% of the Amhara region and treated 18 million people.

Trachoma is one of the leading causes of blindness worldwide, with more than 1.9 million people suffering visual impairment as a result of complications from trachoma. As a member of the Neglected Tropical Disease NGO Network (NNN) and the International Coalition for Trachoma Control (ICTC), the Noor Dubai Foundation is involved in shaping policy for the control of neglected tropical diseases that affect one billion of people in the world.

In line with its strategic direction for comprehensive and long-term programs, in 2019 Noor Dubai launched an eye care program in Katsina State, Nigeria, where all program activities were integrated into the public health system, including the development of local care, human, material and infrastructure capacities and resources.

The program aims to improve the quality of life and socio-economic status of residents of Katsina State and will help reduce blindness and visual impairment in the state by at least 30-40%. To date, more than 24,000 patients have received medical and diagnostic services and 7.5 million people have benefited from public health programs aimed at educating about diseases causing visual impairment.

In 2021, Noor Dubai launched a 5-year program in partnership with the Fred Hollows Foundation, to reduce avoidable blindness by strengthening the eye health system to provide a more comprehensive and sustainable approach in addition to providing eye care services gender-equitable and disability-inclusive in the Barishal Division of Bangladesh.

The program aims to provide effective and affordable prevention, treatment and management of refractive error and diabetic retinopathy, the leading causes of blindness in Barishal.

This program should benefit 25,000 children, 50,000 adults and sensitize and educate nearly 4 million people in Barisal.


Source link

]]>
Cationorm – a preservative-free dry eye treatment https://www.antaresoptical.com/cationorm-a-preservative-free-dry-eye-treatment/ Thu, 21 Apr 2022 04:53:00 +0000 https://www.antaresoptical.com/cationorm-a-preservative-free-dry-eye-treatment/ Cationorm (cationic nanoemulsion) is a preservative-free moisturizing and lubricating emulsion that protects the surface of the eye, reducing the discomfort and irritation of persistent dry eyes caused by prolonged contact lens wear or environmental conditions.1 The therapy’s triple action repairs the lipid layer to reduce evaporation, lubricates and stabilizes the tear film; restores the moisture […]]]>

Cationorm (cationic nanoemulsion) is a preservative-free moisturizing and lubricating emulsion that protects the surface of the eye, reducing the discomfort and irritation of persistent dry eyes caused by prolonged contact lens wear or environmental conditions.1

The therapy’s triple action repairs the lipid layer to reduce evaporation, lubricates and stabilizes the tear film; restores the moisture balance in the muco-aqueous layer of the tear film; and is positively attracted to the ocular surface, to provide long-lasting protection.2-5

Cationorm is suitable for use with contact lenses and is easily administered via a preservative-free multi-dose vial or single-dose ampoules.6

It can be given as one drop, up to four times a day in the affected eye or eyes.6

ALWAYS FOLLOW THE INSTRUCTIONS. IF SYMPTOMS PERSIST, TALK TO YOUR HEALTHCARE PROFESSIONAL.

To order Cationorm, contact Good Optical Services: 1800 814 963 or orders@goodopticalservices.com.au

For more information contact Seqirus Medical Information: 1800 642 865 or aunz.medicalinformation@seqirus.com.

References

  1. Administration of Therapeutic Goods. Australian Therapeutic Goods Register – Public Summary Seqirus PTY LTD – Lubricant, Eye.[cited2021;Availableat:https://wwwebstgagovau/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStorensf&docid=406945E40B6D2CA4CA25843C0042145B&agid=(PrintDetailsPublic)&actionid=1[cited2021;Availablefrom:https://wwwebstgagovau/servlet/dbid=ebs6?PublicHTML/pdfStorensf&docid=406945E40B6D2CA4CA25843C0042145B&agid=(PrintDetailsPublic)&actionid=1[citéen2021 ;Disponiblesur:https://wwwebstgagovau/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStorensf&docid=406945E40B6D2CA4CA25843C0042145B&agid=(PrintDetailsPublic)&actionid=1[cited2021;Availablefrom:https://wwwebstgagovau/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStorensf&docid=406945E40B6D2CA4CA25843C0042145B&agid=(PrintDetailsPublic)&actionid=1
  2. Lallemand, F., et al., Successful improvement of ocular drug delivery using the cationic nanoemulsion, novasorb. J Drug Deliv, 2012. 2012: p. 604204.
  3. Daull, P., F. Lallemand, and JS Garrigue, Advantages of cationic oil-in-water nanoemulsions of cetalkonium chloride for topical delivery of ophthalmic drugs. J Pharm Pharmacol, 2014. 66(4): p. 531-41.
  4. Amrane, M., et al., Ocular tolerance and efficacy of a cationic emulsion in patients with mild to moderate dry eye disease–a randomized comparative study. J Fr Ophthalmol, 2014. 37(8): p. 589-98.
  5. Robert, PY, et al., Efficacy and safety of a cationic emulsion in the treatment of moderate to severe dry eye disease: a randomized controlled study. Eur J Ophthalmol, 2016. 26(6): p. 546-555.
  6. Cationorm product packaging.


Source link

]]>
Mann Eye Institute Expands Innovative EverTears Dry Eye Treatment After Extensive Evaluation https://www.antaresoptical.com/mann-eye-institute-expands-innovative-evertears-dry-eye-treatment-after-extensive-evaluation/ Tue, 19 Apr 2022 14:45:00 +0000 https://www.antaresoptical.com/mann-eye-institute-expands-innovative-evertears-dry-eye-treatment-after-extensive-evaluation/ An industry leader in dry eye treatment has partnered with an innovative medical device start-up to deliver an effective dry eye treatment. ATLANTA, GEORGIA, USA, April 19, 2022 /EINPresswire.com/ — Representatives of ThermaMEDx today announced that the Mann Eye Institute has partnered with the company to evaluate EverTears, the world’s first combination compress self-heating eyepiece […]]]>

An industry leader in dry eye treatment has partnered with an innovative medical device start-up to deliver an effective dry eye treatment.

ATLANTA, GEORGIA, USA, April 19, 2022 /EINPresswire.com/ — Representatives of ThermaMEDx today announced that the Mann Eye Institute has partnered with the company to evaluate EverTears, the world’s first combination compress self-heating eyepiece and pre-moistened cleaning pad.

Carl Sweat, co-founder of ThermaMEDx, said EverTears is designed to provide a convenient and affordable over-the-counter dry eye solution that delivers the precise, controlled heat and eyelid cleansing found in many in-office treatments. EverTears is based on patented technology developed by ThermaMEDx co-founder, Dr. Michel Guillon, to not only relieve dry eye symptoms, but also help restore the eye’s natural tear film when used. in accordance with the instructions.

Mann Eye Institute is the premier provider of LASIK eye surgery, dry eye treatment, and general eye care in the greater Houston area and one of the largest private eye care practices in Texas.

Mann Eye Institute CEO and Executive Director, Dr. Dana Ondrias, explained that providing innovative eye care has long been a key part of the organization’s mission: “Just like our founder, Dr. Mike Mann, Being one of the first physicians in America to perform refractive surgery in 1981, our dedicated staff embraces innovative solutions that advance patient care. She added: “Our doctors and staff started giving the EverTears treatment to dry eye patients late last year and we were pleased with both the patient feedback and the improvement in their condition. underlying MGD.” Based on the test results, the Mann Eye Institute is expanding EverTears to additional Texas sites as the standard of care for dry eye treatment.

ThermaMEDx co-founder Ben Nobles was particularly excited about the expansion plans, saying “Texas is the epicenter of dry eye disease in America and innovative organizations like the Mann Eye Institute are at the forefront. -care to bring the latest technology to their patients.We are committed to supporting the implementation of EverTears as the best treatment for dry eye disease related to Meibomian Gland Dysfunction (MGD).

For more information, please visit thermamedx.com/about-us and https://thermamedx.com/insights-news/

About ThermaMEDx

ThermaMEDx was founded to bring Dr. Michel Guillon’s vision of harnessing thermal energy to provide an accessible and effective treatment for dry eyes and meibomian gland dysfunction. ThermaMEDx is a family business led by our Medical Board of renowned physicians whose mission is to improve patient outcomes by striving to provide the best treatment for dry eyes caused by Meibomian Gland Dysfunction (MGD) available. for home use.

Contact details:

3343 Peachtree Road NE
ETS 145-409
Atlanta, Georgia 30326
United States

Carl Sweat
ThermaMEDx, LLC
+1 833-937-9393
write to us here


Source link

]]>
Longer-acting eye treatment could reduce vision loss for Indigenous Australians https://www.antaresoptical.com/longer-acting-eye-treatment-could-reduce-vision-loss-for-indigenous-australians/ Tue, 19 Apr 2022 01:24:00 +0000 https://www.antaresoptical.com/longer-acting-eye-treatment-could-reduce-vision-loss-for-indigenous-australians/ Indigenous people in Australia experience three times more vision loss than non-indigenous people, creating a worrying gap in vision. This is largely due to diabetic macular edema (DME). Here, the blood vessels at the back of the eye (the retina) are damaged by high blood sugar. Over time, this causes swelling (oedema) of the central […]]]>

Indigenous people in Australia experience three times more vision loss than non-indigenous people, creating a worrying gap in vision.

This is largely due to diabetic macular edema (DME). Here, the blood vessels at the back of the eye (the retina) are damaged by high blood sugar. Over time, this causes swelling (oedema) of the central part of the retina (the macula).

Macular edema blurs central vision, impairing the ability to recognize people’s faces, drive and work, and perform other essential tasks. DMO affects around 23,000 Indigenous people in Australia, most of whom are of working age. Similar trends are reported in other developed states with indigenous populations, including New Zealand, Canada, and the United States.

The good news is that BMD can be treated, with drugs called anti-VEGF agents. We have undertaken a world-first clinical trial to test a longer-acting BMD treatment for Indigenous Australians. In doing so, we have also learned to undertake culturally sensitive research about the country.



Learn more: How can the new Closing the Gap dashboard highlight metrics and targets that are on track?


A longer lasting treatment

When injected into the eye by an ophthalmologist (eye surgeon), anti-VEGF drugs are safe and effective for treating DME. The injections do not hurt, since the eye is anesthetized. The catch is that anti-VEGF agents have a relatively short duration of action, requiring them to be re-administered as often as monthly.

Many Aboriginal patients find it impractical, for a variety of complex reasons, to attend ten to twelve eye appointments per year. So there is a need for an alternative.

Longer acting drugs exist. An example is an implant of dexamethasone (commercially known as Ozurdex(R)), a steroid injected into the eye. The dexamethasone implant only needs to be dosed every three months.

The dexamethasone implant is PBS-approved for BMD in Australia, but has never been evaluated in an aboriginal population. This is important because a possible side effect of steroid medications is increased pressure in the eye. If left untreated, it can lead to a condition called steroid-induced glaucoma.

Glaucoma is thought to occur less frequently in Aboriginal people, suggesting differences in eye pressure physiology between Caucasian and Aboriginal eyes. In addition, the incidence of steroid-induced glaucoma subtype has never been studied in Aboriginal people. This is especially important for people living in remote areas, as glaucoma is a ‘silent disease’, requiring regular check-ups for detection and treatment.

Historical barriers preventing this type of research include cultural and geographic factors, as well as a lack of endorsement from Indigenous health services and “staff champions”.

Kerry Woods, of the Plangermairreenner clan of the Ben Lomond people, is an Indigenous eye health coordinator involved in the study. She said it gave her insight into the treatments available for diabetic eye disease and the monthly injections needed to manage the condition. […] By working closely with patients, I have the opportunity to discuss treatments and find out if they are more satisfied with the new schedule.
Author provided

Not only what to look for, but how

At Lions Eye Institute, we sought to overcome these barriers with the OASIS Study – a world-first clinical trial in ophthalmology to exclusively recruit Indigenous patients.

We framed our study around ten key success factors, including support from all participating Indigenous medical services, free and safe treatment, free transportation, appointment reminders, and cultural safety training for all staff. test staff. Whenever possible, study visits were conducted within the patient’s usual Aboriginal medical service. Study participants could be accompanied by friends, family and staff. This facilitated communication and a sense of security and trust.

Over two years, we recruited 38 aboriginal patients and 52 eyes (some patients had BMD in both eyes). Patients were recruited from both Perth and Western Australia. When they enrolled, they were randomly assigned to receive a dexamethasone implant or an anti-VEGF agent called Avastin. A follow-up was carried out for checks and restatements. After 12 months, we analyzed all our data, in order to compare the safety and effectiveness of the two drugs.

The results showed that patients who received a dexamethasone implant gained an additional four letters on a standard eye chart, which equated to a 6.2% improvement in their vision. Those who received the anti-VEGF agent, meanwhile, lost 5.5 letters on average, a drop of 8.9%.

Taken together, these results represented a visual benefit of 15% (9.5 letters) for patients who received a dexamethasone implant. In concrete terms, this meant that the patients met the visual requirements for a private driving license. Those who received the anti-VEGF agent did not receive it.

This disparity was more pronounced in rural towns, where the dexamethasone implant had a 37% advantage (24 letters) over the anti-VEGF agent.

map of WA with point ids
Trial participants came from across Western Australia.
Author provided

why it works

As we suspected, the reason for the better performance of the dexamethasone implant had to do with its less frequent, and therefore more pragmatic, dosing schedule.

Over 12 months, patients who were to receive four dexamethasone implant injections received an average of 3.3 injections. This means that, on average, they received 82.5% of the scheduled treatments.

Anti-VEGF patients, meanwhile, received 7.2 of their 12 scheduled injections. This equates to only 60% of their scheduled treatments and reflects the difficulty of attending monthly appointments in the real world. Anti-VEGF patients received more than twice as many injections as patients with dexamethasone implants, but ended up with poorer vision.

Not all results were positive. A third of patients who received a dexamethasone implant developed high pressure in the eye – a recognized side effect of steroid injections. Although not painful, it requires treatment with pressure-lowering drops and close follow-up, to prevent glaucoma.

Second, steroid injections accelerate the formation of cataracts (a clouding of the lens of the eye). This requires access to cataract surgery, which is not always easy to arrange in remote locations. Based on these caveats, we developed guidelines for the judicious use of dexamethasone implant in Aboriginal patients, published in March.



Read more: A new way to keep First Nations people living with dementia connected to country, community, family and culture


Reducing the Burden, Bridging the Vision Gap

Although dexamethasone implants are not perfect, we believe the OASIS study offers hope of reducing vision loss and the “burden of treatment” for Indigenous Australians with diabetes.

The ability to perform culturally safe clinical trials means that new treatments could be evaluated in the same way in the future, taking into account patient input through community-controlled research.



Read more: Racism is a public health crisis — but the black death toll isn’t the answer



Source link

]]>
Perioperative Dry Eye Treatment Necessary for Better Postoperative Outcomes https://www.antaresoptical.com/perioperative-dry-eye-treatment-necessary-for-better-postoperative-outcomes/ Mon, 11 Apr 2022 07:00:00 +0000 https://www.antaresoptical.com/perioperative-dry-eye-treatment-necessary-for-better-postoperative-outcomes/ April 18, 2022 5 minute read Source/Disclosures Published by: Disclosures: White Reports Consulting for Aldeyra, Allergan, Avellino, Bausch + Lomb, Johnson & Johnson, Kala, Novartis, Orasis, Rendia, Santen, Sight Sciences, Sun and TearLab; speaking for Allergan, Kala, Novartis, Santen and Sun; and have a stake in Orasis. ADD A SUBJECT TO […]]]>

April 18, 2022

5 minute read


Source/Disclosures


Disclosures: White Reports Consulting for Aldeyra, Allergan, Avellino, Bausch + Lomb, Johnson & Johnson, Kala, Novartis, Orasis, Rendia, Santen, Sight Sciences, Sun and TearLab; speaking for Allergan, Kala, Novartis, Santen and Sun; and have a stake in Orasis.


We have not been able to process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

One of the many important benefits of my membership in the CEDARS/ASPENS Society is our ability to reach out for “curbside consultations”.

This morning, as I prepared for clinic hours, I read through the latest, a request from Tim Page of Michigan for advice on a case referred to him involving a dissatisfied patient with the multifocal IOL. I’m pretty sure all of the cataract surgeons in our group implant some or all of the options in this class; preoperative decision-making (e.g. what type of IOL to use) and postoperative challenges are fertile fields for our discussions.

Darrell E. White, MD

Darrell E. White

Tim’s colleague noted that the central ring of the multifocal IOL was bisected by the edge of the pupil on the nasal side, implying that the IOL was slightly off center temporally. However, when the pupil was dilated, the IOL appeared perfectly centered on both the pupil and the line of sight. Did the patient require laser pupilloplasty? Should the surgeon put on a capsular tension ring? Perhaps an IOL swap was the answer, removing the multifocal IOL in favor of a monofocal IOL. All sorts of measurements followed – we all like to ask about things like kappa angle, mu tuning and higher order aberrations – but at least part of the answer was obvious when an image of the topography appeared: the patient had a dry eye.

All the dry eye experts (DED) in our group were waiting for this shoe to drop. The patient had not been treated for DED before the operation and was not taking any medication that would treat it at this stage. By the time all shared data was obtained, the patient was far enough away from surgery that he was no longer receiving typical perioperative drops, so he was not even taking topical steroids. While the jury will be out on the more exotic options mentioned above, the majority of respondents on this thread agreed that the first thing to do is to aggressively treat dryness before making decisions about whether a additional surgery was warranted or not.

Whether or not you plan to use a presbyopia-correcting IOL, whether it’s a multifocal or extended depth-of-field (EDOF) IOL, dryness can derail the refractive cataract train even after surgery. technically perfect. Refractive laser surgery of any kind runs a similar risk. It is important to remember that any anterior segment surgery that involves cutting the cornea, conjunctiva, or both is a pro-inflammatory experience that will lead to increased dryness on all ocular surfaces. Eric Donnenfeld and Bill Trattler were among the first surgeons to explore this, and both showed that cataract and laser refraction procedures caused all measurable parameters of dry eye to worsen. In a typically concise summary, Dr. Donnenfeld describes the surgeon’s conundrum: If you diagnose preop DED, that’s the patient’s problem; if you diagnose it after the operation, that’s up to you.

This is not a problem unique to advanced IOL implantation, although the higher expectations shared by surgeons and patients make it more difficult. Dryness not only affects postoperative vision and visual quality, but it can also lead to significant postoperative refractive surprises when it affects our baseline preoperative measurements. Dr Trattler shared a now famous case in which the original measurements showed 2 D of cylinder. A new measurement after a few weeks of treatment with artificial tears showed a perfectly spherical cornea and refraction. Alice Epitropoulos wins the best video award showing real-time improvement in preoperative measurements after stimulating a patient’s tear production with TrueTear (Allergan), eliminating the pseudocylinder.

Our approach to this problem at SkyVision is to aggressively seek out even the smallest sign or symptom of DED during every preoperative examination for cataract and refractive surgeries. The ASCRS algorithm is especially useful if you don’t typically focus on diagnosing and treating DED. Led by Chris Starr, the American Society of Cataract and Refractive Surgery research group encourages surgeons to use a “look, lift, push, pull” slit lamp examination. If DED is present, then consideration is given to whether it is or will be visually significant and will have an effect on preoperative measurements or postoperative outcomes. We are much more aggressive, especially if the plan is to insert a multifocal or EDOF IOL. A single point of staining, high tear osmolarity, or wobbly topography, and we’ll treat.

By the way, of all the DED algorithms that currently exist, the ASCRS offering is the most useful for the majority of ophthalmologists. Whether you are considering mitigating the effect of DED on preoperative measures, postoperative visual quality, or the all-too-common transient flare-ups of DED symptoms, finding the fastest, most direct solution is the solution in the majority of case. Almost all patients will benefit from aggressive lubrication with high quality artificial tears. Do yourself (and your patient) a favor and strongly encourage them to use preservative-free varieties. If you think chronic treatment is going to be necessary, start by all means preop. There is nothing to be gained by waiting after the procedure to write a prescription for Restasis (cyclosporine ophthalmic emulsion 0.05%, Allergan) (or “Fauxstasis”), Cequa (cyclosporine ophthalmic solution 0.09% , Sun Pharmaceutical) or Xiidra (lifitegrast ophthalmic solution 5%, Novartis).

To get the fastest results, just remember two words: Ster. Rigid.

Remember White’s DED treatment rule: you can’t make an asymptomatic patient feel better. You and your patient would like to have the surgical experience as quickly as possible. Using this as justification for treating what the patient perceives as asymptomatic DED will usually convince them. The quickest route to correcting the deleterious effects of DED on the ocular surface is to prescribe topical steroids.

You can choose any steroid from the myriad of choices we all have, but my bias is to choose one that gives you the flexibility to leave your patient on medication during the perioperative period. Do you have a patient with a very dry eye, with a lot of spots and a tear break-up time measured in milliseconds? We love fluorometholone, especially fluorometholone acetate found in Flarex (Eyevance Pharmaceuticals). In its Phase 3 trial, it was subjected to a head-to-head comparison with Pred Forte (Prednisolone Acetate Ophthalmic Solution 1%, Allergan) (like we’ll never see that again!) and found to be just as potent with a fraction of the risk.

In the majority of cases where we need rapid rehabilitation of the ocular surface with the possibility of continuation of treatment, we go to the loteprednol section of the pharmacy. The best tested of these, and the only one with a label indication for DED, is Eysuvis (loteprednol etabonate ophthalmic suspension 0.25%, Kala Pharmaceuticals). Only two subjects in the extended FDA safety trial had IOP increases of 5 mm Hg or greater. That said, there are several other good branded options such as the Lotemax franchise (loteprednol etabonate, Bausch + Lomb), and in some markets there are reasonable generics as well. Four times daily for 2 weeks, then re-measure for your IOL calculations, followed by twice daily, if needed, during the perioperative period.

Find all preop DED patients. Come on everyone Tom Cruise/Superior gun “need for speed” and treat them in a way that follows your usual surgical routines as much as possible. And if you think the patients will need chronic treatment, start your immunomodulator preop. Keep postop DED from becoming your problem.


Source link

]]>
Al-Shifa Trust brings the latest technology for eye treatment https://www.antaresoptical.com/al-shifa-trust-brings-the-latest-technology-for-eye-treatment-2/ Sun, 10 Apr 2022 01:00:00 +0000 https://www.antaresoptical.com/al-shifa-trust-brings-the-latest-technology-for-eye-treatment-2/ Rawalpindi: Al-Shifa Trust Eye Hospital has introduced a revolutionary new Swiss technology for eye treatment, which will benefit many people in Pakistan. Al-Shifa has become the first facility in Asia to use a femtosecond laser developed by a Swiss company to perform Bowmann layer grafting for the treatment of keratoconus, an eye disease that affects […]]]>

Rawalpindi: Al-Shifa Trust Eye Hospital has introduced a revolutionary new Swiss technology for eye treatment, which will benefit many people in Pakistan.

Al-Shifa has become the first facility in Asia to use a femtosecond laser developed by a Swiss company to perform Bowmann layer grafting for the treatment of keratoconus, an eye disease that affects the cornea, Professor Dr. Wajid Ali Khan said. Chief Medical Services Trust.

He said the latest technology will not only enable our ophthalmologists to provide better eye care to their patients, but we will also train doctors working in other institutions.

He said around two hundred thousand people needed the procedure, but the trust could perform 800 surgeries a year due to limited supply. With the help of this latest technology, the layers of a cornea can be used to treat two to three patients, he said. Senior Engineer of Ziemer Ophthalmic Systems AG Fritz Meyer who was visiting Pakistan informed that this treatment takes a very thin layer of the donor cornea and is placed in a pocket of the diseased cornea of ​​the suffering patient. This procedure strengthens the weak cornea, thus avoiding the need for a complete corneal transplant. So far, twenty patients have been successfully treated with this technique at Al Shifa Eye Hospital, which is encouraging, he added.

It can be mentioned that the trust was established in 1991, fighting against blindness and introducing many advanced treatment options over the past three decades.

In 1992, Department of Cornea and Refractive Surgery was established at Al-Shifa Eye Hospital, Rawalpindi. Later, radial keratotomy was introduced in 1993 to treat patients who wear glasses. Excimer laser was introduced in 1995. Amniotic membrane transplant and limbal stem cell transplant started in 2006 and amniotic membrane bank was also established.

To treat patients with keratoconus in which the cornea becomes thin and tapered, a new treatment called collagen cross-linking was launched in 2008. This treatment was not even offered in countries like the United States and Canada. Over 5000 patients have benefited from this treatment since then and most of them are children and young adults.

In 2008, the trust created the first international standard Eye Bank with technical support from Eversight Eye Bank Michigan USA. Al-Shifa has the largest corneal transplant center in Pakistan. Al-Shifa shares his experiences with domestic and foreign doctors by presenting his work at domestic and international conferences and publishing it in medical journals.


Source link

]]>